Anticonvulsant Sulfonamides in Epilepsy and Other Neurological Disorders

Masako Kinoshita, MD, PhD
Department of Neurology, Utano National Hospital, National Hospital Organization, Kyoto, Japan

Series: Neurology – Laboratory and Clinical Research Developments
BISAC: MED057000

Clear

$58.00

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Epilepsy is one of the most common neurological disorders, characterized by recurrent epileptic seizures, affecting all age groups which exhibit a wide range of symptoms and severities. Once seizures are well-controlled without impeding side effects or co-morbidities, patients with epilepsy can participate in various social activities and can maintain a good quality of life. In order to achieve the condition, there are emerging new antiepileptic drugs with sufficient efficacy to both partial and generalized seizures, with minimum adverse events, applicable to both adults and children, and used as monotherapy or add-on therapy. Sulfonamide drugs have been originally developed as potent antimicrobial agents, and several antiepileptic sulfonamides show efficacy in epilepsy.

This book will describe recent developments in epilepsy therapy, mechanisms of action, uses in epilepsy, and side effects of sulfonamide antiepileptic drugs. Not only practical uses in the field of epilepsy, but also other possible effects for other neurological disorders of these drugs are summarized. Moreover, recent topics around a wide variety of sulfonamide drugs will be covered. The author hopes to provide useful information to medical doctors, nurses, caregivers, pharmacists, and researchers engaging in epileptology, neurology and neuropharmacology, and anybody who is interested in or deals with patients with epilepsy. (Imprint: Nova Biomedical )

Preface

Chapter 1. History of Antibacterial Sulfonamides

Chapter 2. Non-Antibacterial Sulfonamides

Chapter 3. Anticonvulsant Sulfonamides – Acetazolamide

Chapter 4. Anticonvulsant Sulfonamides - Sulthiame

Chapter 5. Anticonvulsant Sulfonamides - Topiramate

Chapter 6. Anticonvulsant Sulfonamides – Zonisamide

Author Contact Information

Index

Chapter 1

Andrès E, Maloisel F. Idiosynctatic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol 2008; 15: 15-21.


Buttle GAH, Gray WH, Stephenson D. Protection of mise against streptococcal and other infections by p-aminobenzensulfonamide and related substances. Lancet. 1936:1;1286-1290.


Bushby SR, Hitchings GH. Trimethoprim, a sulphonamide potentiator. Br J Pharmacol Chemother. 1968 May;33(1):72-90.
Colebrook L, Kenny M. Treatment of human puerperal infections, and of experimental infections in mice, with prontosil. Lancet. 1936a:1;1279-1286.
Colebrook L, Kenny M. Treatment with prontosil of puerperal infections due to haemolytic streptococci. Lancet. 1936b;2:1319-1322.
Cribb AE, Lee BL, Trepanier LA, Spielberg SP. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev. 1996 Mar;15(1):9-50.
Dever LA, Dermody TS. Mechanisms of bacterial resistance to antibiotics. Arch Intern Med. 1991 May;151(5):886-895.
Domagk GJ. Ein Beitrag zur Chemotherapie der bakteriellen infektionen. Deutsch Med. 1935; 61: 250-253.
FDA Consumer magazine. Sulfanilamide Disaster. June 1981 Issue. Web. 15 Dec 2013. .
Fildes P. A rational approach to research in chemotherapy. Lancet. 1940;1: 955-957.
Foerster R. Sepsis im anschluß an ausgedehnte periporitis: heilung durch streptozon. Zentralbl Haut Geschlechtskr Grenzgeb. 1933;45:549-550.
Fraunfelder FT, Meyer SM, Bagby GC Jr, Dreis MW. Hematologic reactions to carbonic anhydrase inhibitors. Am J Ophthalmol. 1985 Jul 15;100(1):79-81.
Harrold M, Zavod R. Chapter 4; Solving pH and pKa problems. In: Basic Concepts in Medicinal Chemistry. American Society of Health-System Pharmacists, Maryland, 2013.
Landy M, Larkum NW, Oswald EJ, Streightoff F. Increased synthesis of p-aminobenzoic acid associated with the development of sulfonamide resistance in staphylococcus aureus. Science. 1943 Mar 19;97(2516):265-267.
Levaditi C, Vaisman A. Action curative du 4’-sulfamide-2’,4’-diaminoazobénzéne et de quelques derives similaires dans le streptococcie experimentale. C.R. Soc. Biol. 1935:119;946-969.
Macleod CM. The inhibition of the bacteriostatic action of sulfonamide drugs by substances of animal and bacterial origin. J Exp Med. 1940 Aug 31;72(3):217-232.
Matlaga BR, Shah OD, Assimos DG. Drug-Induced Urinary Calculi. Rev Urol. 2003 Fall;5(4):227-231.
Nobelprize.org. “Gerhard Domagk - Biographical”. Nobel Media AB 2013. Web. 15 Dec 2013. .
Ponka D. Approach to managing patients with sulfa allergy: use of antibiotic and nonantibiotic sulfonamides. Can Fam Physician. 2006 Nov;52(11):1434-1438.
Qiang Z, Adams C. Potentiometric determination of acid dissociation constants (pKa) for human and veterinary antibiotics. Water Res. 2004 Jul;38(12):2874-2890.
Strom BL, Schinnar R, Apter AJ, Margolis DJ, Lautenbach E, Hennessy S, Bilker WB, Pettitt D. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003 Oct 23;349(17):1628-1635.
Swedberg G, Sköld O. Characterization of different plasmid-borne dihydropteroate synthases mediating bacterial resistance to sulfonamides. J Bacteriol. 1980 Apr;142(1):1-7.
TIME Magazine. Medicine: Prontosil. December 28, 1936.
Tréfouël J, Tréfouël Mme J, Nitti F, Bovet D. Activité du p-aminophénylsulfamide sur les infections expérimentales de la souris et du lapin. C.R. Soc. Biol. Paris. 1936:120;756-758.
Weisman RA, Brown GM. The biosynthesis of folic acid. V. Characteristics of the enzyme system that catalyzes the synthesis of dihydropteroic acid. J Biol Chem. 1964;239:326-331.
Wiedemann B. Mechanisms of antibiotic resistance and their dissemination of resistance genes in the hospital environment. Infect Control. 1983 Nov-Dec;4(6):444-447.
Wise EM Jr, Abou-Donia MM. Sulfonamide resistance mechanism in Escherichia coli: R plasmids can determine sulfonamide-resistant dihydropteroate synthases. Proc Natl Acad Sci U S A. 1975 Jul;72(7):2621-2625.
Woods DD. The relation of p-aminobenzoic acid to the mechanism of the action of sulfanilamide. Brit. J. Exptl. Path. 1940;21:74-90.
Wulf NR, Matuszewski KA. Sulfonamide cross-reactivity: is there evidence to support broad cross-allergenicity? Am J Health Syst Pharm. 2013 Sep 1;70(17):1483-1494.
Yun MK, Wu Y, Li Z, Zhao Y, Waddell MB, Ferreira AM, Lee RE, Bashford D, White SW. Catalysis and sulfa drug resistance in dihydropteroate synthase. Science. 2012 Mar 2;335(6072):1110-1114.

Chapter 2

Alterio V, Vitale RM, Monti SM, Pedone C, Scozzafava A, Cecchi A, De Simone G, Supuran CT. Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. J Am Chem Soc. 2006 Jun 28;128(25):8329-8335.
Arechederra RL, Waheed A, Sly WS, Supuran CT, Minteer SD. Effect of sulfonamides as carbonic anhydrase VA and VB inhibitors on mitochondrial metabolic energy conversion. Bioorg Med Chem. 2013 Mar 15;21(6):1544-1548.
Balsells J, Walsh PJ. Asymmetric cyclopropanation of allylic alcohols employing Sulfonamide/Schiff base ligands. J Org Chem. 2000 Aug 11;65(16):5005-5008.
Borras J, Scozzafava A, Menabuoni L, Mincione F, Briganti F, Mincione G, Supuran CT. Carbonic anhydrase inhibitors: synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing 8-quinoline-sulfonyl moieties: is the tail more important than the ring? Bioorg Med Chem. 1999 Nov;7(11):2397-2406.
Briganti F, Tilli S, Mincione G, Mincione F, Menabuoni L, Supuran CT. Carbonic anhydrase inhibitors. metal complexes of 5-(2-chlorophenyl)-1,3,4-thiadiazole-2-sulfonamide with topical intraocular pressure lowering properties: the influence of metal ions upon the pharmacological activity. J Enzyme Inhib. 2000;15(2):185-200.
Carlson H, Ronne-Engström E, Ungerstedt U, Hillered L. Seizure related elevations of extracellular amino acids in human focal epilepsy. Neurosci Lett. 1992 Jun 8;140(1):30-32.
Chatterjee A, Bennur TH, Joshi NN. Truly catalytic and enantioselective pinacol coupling of aryl aldehydes mediated by chiral Ti(III) complexes. J Org Chem. 2003 Jul 11;68(14):5668-5671.
Coleman JE. Mechanism of action of carbonic anhydrase. Subtrate, sulfonamide, and anion binding. J Biol Chem. 1967 Nov 25;242(22):5212-5219.
Cozzi PG. Metal-Salen Schiff base complexes in catalysis: practical aspects. Chem Soc Rev. 2004 Sep 10;33(7):410-421.
De Simone G, Supuran CT. Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target. Biochim Biophys Acta. 2010 Feb;1804(2):404-409.
Fox CL Jr. Silver sulfadiazine--a new topical therapy for Pseudomonas in burns. Therapy of Pseudomonas infection in burns. Arch Surg. 1968 Feb;96(2):184-188.
Gasparová R, Lácová M. Reactions of 3-formylchromone with active methylene and methyl compounds and some subsequent reactions of the resulting condensation products. Molecules. 2005 Aug 31;10(8):937-960.
Güzel O, Innocenti A, Scozzafava A, Salman A, Supuran CT. Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inhibitors of human mitochondrial isoforms VA and VB. Bioorg Med Chem. 2009 Jul 15;17(14):4894-4899.
Hirayama N, Taga J, Oshima S, Honjo T. Sulfonamide-type di-Schiff base ligands as chelate extraction reagents for divalent metal cations. Anal Chim Acta. 2002;466:295-301.
Hosseinimehr SJ, Shafiee A, Mozdarani H, Akhlagpour S, Froughizadeh M. Radioprotective effects of 2-imino-3-[(chromone-2-yl)carbonyl] thiazolidines against gamma-irradiation in mice. J Radiat Res. 2002 Sep;43(3):293-300.
Ilies MA, Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors. Part 91. Metal complexes of heterocyclic sulfonamides as potential pharmacological agents in the treatment of gastric acid secretion imbalances. Met Based Drugs. 2000;7(2):57-62.
Janbon M, Chaptal J, Vedel A, Schaap J. [Accidents hypoglycémiques graves par un sulfamidothiodiazol (le VK 57 ou 2254 RP)]. Montpellier Med. 1942;441:21-22. French.
Kannan KK, Notstrand B, Fridborg K, Lövgren S, Ohlsson A, Petef M. Crystal structure of human erythrocyte carbonic anhydrase B. Three-dimensional structure at a nominal 2.2-A resolution. Proc Natl Acad Sci U S A. 1975 Jan;72(1):51-55.
Kawata Y, Okada M, Murakami T, Mizuno K, Wada K, Kondo T, Kaneko S. Effects of zonisamide on K+ and Ca2+ evoked release of monoamine as well as K+ evoked intracellular Ca2+ mobilization in rat hippocampus. Epilepsy Res. 1999 Jul;35(3):173-182.
Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem. 1971 Apr 25;246(8):2561-2573.
Komatsu M, Okamura Y, Hiramatsu M. Free radical scavenging activity of zonisamide and its inhibitory effect on lipid peroxide formation in iron-induced epileptogenic foci of rats. Neurosciences. 1995;21:23-29.
LaRoche SM, Helmers SL. The new antiepileptic drugs: Clinical applications. JAMA 2004;291:615-620.
LaRoche SM. A new look at the second-generation antiepileptic drugs: A decade of experience. Neurologist 2007;13:133-139.
Loubatières-Mariani MM. [The discovery of hypoglycemic sulfonamides]. J Soc Biol. 2007;201(2):121-125. French.
Lyseng-Williamson KA, Yang LP. Topiramate: a review of its use in the treatment of epilepsy. Drugs. 2007;67(15):2231-2256.
Makio H, Kashiwa N, Fujita T. FI Catalysts: a new family of high performance catalysts for olefin polymerization. Adv Synth Catal. 2002;344: 477-493.
Maren TH, Conroy CW. A new class of carbonic anhydrase inhibitor. J Biol Chem. 1993 Dec 15;268(35):26233-26239.
Meldrum NU, Roughton FJW. Some properties of carbonic anhydrase, the carbon dioxide enzyme present in blood. J Physiol (London). 1932;75:15-16.
Menabuoni L, Scozzafava A, Mincione F, Briganti F, Mincione G, Supuran CT. Carbonic anhydrase inhibitors. Water-soluble, topically effective intraocular pressure lowering agents derived from isonicotinic acid and aromatic/heterocyclic sulfonamides: is the tail more important than the ring? J Enzyme Inhib. 1999;14(6):457-474.
Micheels J, Moray V, Castermans A. A ten-year retrospective study of sepsis in severely burned patients treated with or without silversulfadiazinate. Scand J Plast Reconstr Surg. 1979;13(1):85-87.
Mincione F, Menabuoni L, Briganti F, Mincione G, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IV with N-hydroxysulfonamides--a novel class of intraocular pressure lowering agents. J Enzyme Inhib. 1998 Jul;13(4):267-284.
Monti SM, Supuran CT, De Simone G. Anticancer carbonic anhydrase inhibitors: a patent review (2008 - 2013). Expert Opin Ther Pat. 2013;23(6):737-749.
Mori A, Noda Y, Packer L. The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res. 1998;30:153-158.
Mori A, Yokoi I, Noda Y, Willmore LJ. Natural antioxidants may prevent posttraumatic epilepsy: a proposal based on experimental animal studies. Acta Med Okayama. 2004 Jun;58(3):111-118.
Nalam MN, Peeters A, Jonckers TH, Dierynck I, Schiffer CA. Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 protease. J Virol. 2007 Sep;81(17):9512-9518.
Noda Y, Mori A, Packer L. Zonisamide inhibits nitric oxide synthase activity induced by N-methyl-D-aspartate and buthionine sulfoximine in the rat hippocampus. Res Commun Mol Pathol Pharmacol. 1999;105:23-33.
Nuti E, Orlandini E, Nencetti S, Rossello A, Innocenti A, Scozzafava A, Supuran CT. Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates. Bioorg Med Chem. 2007 Mar 15;15(6):2298-2311.
Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, Fukushima Y. Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995;22:193-205.
Okada M, Kawata Y, Mizuno K, Wada K, Kondo T, Kaneko S. Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br J Pharmacol. 1998;124:1277-1285.
Okada M, Hirano T, Kawata Y, Murakami T, Wada K, Mizuno K, Kondo T, Kaneko S. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res. 1999;34:187-197.
Owen AJ, Ijaz S, Miyashita H, Wishart T, Howlett W, Shuaib A. Zonisamide as a neuroprotective agent in an adult gerbil model of global forebrain ischemia: a histological, in vivo microdialysis and behavioral study. Brain Res. 1997;770:115-122.
Pasquale TR, Tan JS. Nonantimicrobial effects of antibacterial agents. Clin Infect Dis. 2005 Jan 1;40(1):127-135.
Pastorek J, Pastoreková S, Callebaut I, Mornon JP, Zelník V, Opavský R, Zat'ovicová M, Liao S, Portetelle D, Stanbridge EJ, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene. 1994 Oct;9(10):2877-2888.
Pastoreková S, Parkkila S, Parkkila AK, Opavský R, Zelník V, Saarnio J, Pastorek J. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology. 1997 Feb;112(2):398-408.
Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem. 2004 Jun;19(3):199-229.
Puccetti L, Fasolis G, Vullo D, Chohan ZH, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3096-3101.
Ridderstråle Y, Wistrand PJ, Brechue WF. Membrane-associated CA activity in the eye of the CA II-deficient mouse. Invest Ophthalmol Vis Sci. 1994 Apr;35(5):2577-2584.
Rock DM, Macdonald RL, Taylor CP. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res. 1989;3:138-143.
Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med. 2004;10:685-692.
Santos MA, Marques S, Vullo D, Innocenti A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1538-1543.
Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res. 1987;413:185-188.
Schwartzkroin PA. Arresting epileptogenesis: the current challenge. In Rho JM, Sankar R, Cavazos JE (eds). Epilepsy: scientific foundations of clinical practice. New York: Marcel Dekker Inc. p 483-96. 2004.
Scozzafava A, Briganti F, Mincione G, Menabuoni L, Mincione F, Supuran CT. Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route. J Med Chem. 1999 Sep 9;42(18):3690-700.
Sudha K, Rao AV, Rao A. Oxidative stress and antioxidants in epilepsy. Clin Chim Acta. 2001;303:19-24.
Supuran CT, Scozzafava A. Novel aromatic/heterocyclic sulfonamides and their metal complexes as inhibitors of carbonic anhydrase isozymes I, II and IV. J Enzyme Inhib. 1997 Apr;12(1):37-51.
Supuran CT, Scozzafava A, Mincione F, Menabuoni L, Briganti F, Mincione G, Jitianu M. Carbonic anhydrase inhibitors. Part 60(#). The topical intraocular pressure-lowering properties of metal complexes of a heterocyclic sulfonamide: influence of the metal ion upon biological activity. Eur J Med Chem. 1999 Jul-Aug;34(7-8):585-595.
Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev. 2003 Mar;23(2):146-189.
Supuran CT, Scozzafava A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg Med Chem. 2007 Jul 1;15(13):4336-50.
Supuran CT. Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Des. 2008;14(7):641-648.
Temperini C, Cecchi A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21.
Thiry A, Dogné JM, Masereel B, Supuran CT. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci. 2006 Nov;27(11):566-573.
Timotheatou D, Ioannou PV, Scozzafava A, Briganti F, Supuran CT. Carbonic anhydrase interaction with lipothioars enites: a novel class of isozymes I and II inhibitors. Met Based Drugs. 1996;3(6):263-268.
Ueda Y, Doi T, Tokumaru J, Willmore LJ. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res. 2003 Aug 19;116(1-2):1-6.
White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia. 1999;40(Suppl 5):S2-10.
Winum JY, Thiry A, Cheikh KE, Dogné JM, Montero JL, Vullo D, Scozzafava A, Masereel B, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of isoforms I, II, IV, VA, VII, IX, and XIV with sulfonamides incorporating fructopyranose-thioureido tails. Bioorg Med Chem Lett. 2007 May 15;17(10):2685-2691.
Winum JY, Poulsen SA, Supuran CT. Therapeutic applications of glycosidic carbonic anhydrase inhibitors. Med Res Rev. 2009 May;29(3):419-435.
Winum JY, Colinas PA, Supuran CT. Glycosidic carbonic anhydrase IX inhibitors: a sweet approach against cancer. Bioorg Med Chem. 2013 Mar 15;21(6):1419-1426.
Wruble M. Colloidal silver sulfonamides. J Am Pharm Assoc. 1943;32:80-82.
Xu J, Gao K. Use of UV-A energy for photosynthesis in the red macroalga Gracilaria lemaneiformis. Photochem Photobiol. 2010 May-Jun;86(3):580-585.
Zhu W, Rogawski MA. Zonisamide depresses excitatory synaptic transmission by a presynaptic action. Epilepsia. 1999;40(Suppl 7):245 [Abstract].
Zhu Z, Zhu S, Liu D, Cao T, Wang L, Tepel M. Thiazide-like diuretics attenuate agonist-induced vasoconstriction by calcium desensitization linked to Rho kinase. Hypertension. 2005 Feb;45(2):233-239.

Chapter 3

Chapron DJ, Sweeney KR, Feig PU, Kramer PA. Influence of advanced age on the disposition of acetazolamide. British Journal of Clinical Pharmacology 1985;19:363-71.
Forsythe WI, Owens JR, Toothill C. Effectiveness of acetazolamide in the treatment of carbamazepine-resistant epilepsy in children. Developmental Medicine and Child Neurology 1981;23:761-769.
Holowach J, Thurston DL. A clinical evaluation of acetazolamide (Diamox) in the treatment of epilepsy in children. Journal of Pediatrics 1958;53:160-171.
Hsieh PC, Chen SM, Guo YH, Kuan TS, Yen WJ, Chang WC, Lin YC. Effect of acetazolamide for long-lasting paroxysmal dystonia in a patient with multiple sclerosis: a case report and review of literature. Neuropsychiatr Dis Treat. 2013;9:445-448.
Ilg W, Bastian AJ, Boesch S, Burciu RG, Celnik P, Claaßen J, Feil K, Kalla R, Miyai I, Nachbauer W, Schöls L, Strupp M, Synofzik M, Teufel J, Timmann D. Consensus Paper: Management of Degenerative Cerebellar Disorders. Cerebellum. 2013 Nov 13. [Epub ahead of print]
Katayama F, Miura H, Takanashi S. Long-term effectiveness and side effects of acetazolamide as an adjunct to other anticonvulsants in the treatment of refractory epilepsies. Brain and Development 2002;24:150-154.
Kuroda S, Kamiyama H, Abe H, Houkin K, Isobe M, Mitsumori K. Acetazolamide test in detecting reduced cerebral perfusion reserve and predicting long-term prognosis in patients with internal carotid artery occlusion. Neurosurgery. 1993 Jun;32(6):912-8; discussion 918-919.
Lim LL, Foldvary N, Mascha E, Lee J. Acetazolamide in women with catamenial epilepsy. Epilepsia 2001;42:746-749.
Matsuyama Z, Murase M, Shimizu H, Aoki Y, Hayashi M, Hozumi I, Inuzuka T. A novel insertion mutation of acetazolamide-responsive episodic ataxia in a Japanese family. Neurol Sci. 2003 Jun 15;210(1-2):91-93.
Matthews E, Hanna MG. Muscle channelopathies: does the predicted channel gating pore offer new treatment insights for hypokalemic periodic paralysis? J Physiol. 2010 Jun 1;588(Pt 11):1879-1886.
Matthews E, Portaro S, Ke Q, Sud R, Haworth A, Davis MB, Griggs RC, Hanna MG. Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype. Neurology. 2011 Nov 29;77(22):1960-1964.
Oles KS, Penry K, Cole DLW, Howard G. Use of acetazolamide as an adjunct to carbamazepine in refractory partial seizures. Epilepsia 1989;30:74-78.
Poca MA, Sahuquillo J. Short-term medical management of hydrocephalus. Expert Opin Pharmacother. 2005 Aug;6(9):1525-1538.
Reiss WG, Oles KS. Acetazolamide in the treatment of seizures. Annals of Pharmacotherapy 1996;30:514-519.
Resor SR, Resor LD. Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy. Neurology 1990;40:1677-1681.
Richter A, Hamann M. The carbonic anhydrase inhibitor acetazolamide exerts antidystonic effects in the dt(sz) mutant hamster. Eur J Pharmacol. 2004 Oct 11;502(1-2):105-108.
Russell D, Dybevold S, Kjartansson O, Nyberg-Hansen R, Rootwelt K, Wiberg J. Cerebral vasoreactivity and blood flow before and 3 months after carotid endarterectomy. Stroke. 1990 Jul;21(7):1029-1032.
Scoggan KA, Friedman JH, Bulman DE. CACNA1A mutation in a EA-2 patient responsive to acetazolamide and valproic acid. Can J Neurol Sci. 2006 Feb;33(1):68-72.
Sethi KD, Hess DC, Huffnagle VH, Adams RJ. Acetazolamide treatment of paroxysmal dystonia in central demyelinating disease. Neurology. 1992 Apr;42(4):919-921.
Soderman P, Hartvig P, Fagerlund C. Acetazolamide excretion into breast milk. British Journal of Clinical Pharmacology 1984;17:599-600.
Tawil R, Moxley RT, Griggs RC. Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders. Neurology 1993;43:1105-1106.
Thurtell MJ, Wall M. Idiopathic intracranial hypertension (pseudotumor cerebri): recognition, treatment, and ongoing management. Curr Treat Options Neurol. 2013 Feb;15(1):1-12.
Vaziri ND, Saiki J, Barton CH, Rajudin M, Ness RL. Hemo dialyzability of acetazolamide. South Medical Journal 1980;73:422-423.
Watson WA, Garrelts JC, Zinn PD, Garriott JC, McLemore TL, Clementi WA. Chronic acetazolamide intoxication. Clinical Toxicology 1984;22:549–63.
Yabe I, Sasaki H, Yamashita I, Takei A, Tashiro K. Clinical trial of acetazolamide in SCA6, with assessment using the Ataxia Rating Scale and body stabilometry. Acta Neurol Scand. 2001 Jul;104(1):44-47.

Chapter 4

Aupers J, Carlisle CH, Lindley PF. The crystal and molecular structure of benzenesulphonamide-p-(tetrahydro-2H-1,2-thiazin-2-yl)-S,S-dioxide. Acta Cryst. 1974;B30:1228-1233.
Aviram A, Czaczkes JW, Rosenmann E. Acute renal failure associated with sulthiame. Lancet. 1965 Apr 10;1(7389):818.
Bast T, Völp A, Wolf C, Rating D; Sulthiame Study Group. The influence of sulthiame on EEG in children with benign childhood epilepsy with centrotemporal spikes (BECTS). Epilepsia. 2003 Feb;44(2):215-220.
Borggraefe I, Bonfert M, Bast T, Neubauer BA, Schotten KJ, Maßmann K, Noachtar S, Tuxhorn I, May TW, Heinen F; German HEAD Study Group. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). Eur J Paediatr Neurol. 2013 Sep;17(5):507-514.
Borusiak P, Langer T, Heruth M, Karenfort M, Bettendorf U, Jenke AC. Antiepileptic drugs and bone metabolism in children: data from 128 patients. J Child Neurol. 2013 Feb;28(2):176-183.
Caraballo RH, Veggiotti P, Kaltenmeier MC, Piazza E, Gamboni B, Lopez Avaria MF, Noli D, Adi J, Cersosimo R. Encephalopathy with status epilepticus during sleep or continuous spikes and waves during slow sleep syndrome: a multicenter, long-term follow-up study of 117 patients. Epilepsy Res. 2013 Jul;105(1-2):164-173.
Debus OM, Kurlemann G; Study group. Sulthiame in the primary therapy of West syndrome: a randomized double-blind placebo-controlled add-on trial on baseline pyridoxine medication. Epilepsia. 2004 Feb;45(2):103-108.
Doose H, Baier WK, Ernst JP, Tuxhorn I, Völzke E. Benign partial epilepsy--treatment with sulthiame. Dev Med Child Neurol. 1988 Oct;30(5):683-684.
Eadie MJ. Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance. Clin Pharmacokinet. 1991 Jul;21(1):27-41.
Engler F, Maeder-Ingvar M, Roulet E, Deonna T. Treatment with Sulthiame (Ospolot) in benign partial epilepsy of childhood and related syndromes: an open clinical and EEG study. Neuropediatrics. 2003 Apr;34(2):105-109.
Fejerman N, Caraballo R, Cersósimo R, Ferraro SM, Galicchio S, Amartino H. Sulthiame add-on therapy in children with focal epilepsies associated with encephalopathy related to electrical status epilepticus during slow sleep (ESES). Epilepsia. 2012 Jul;53(7):1156-1161.
Garland HG, Stewart DSS. Sulthiame in Treatment of Epilepsy. Br Med J. 1964 February 22;1(5381):474-476.
Green JR, Troupin AS, Halperm LM, Friel P, Kanarek P. Sulthiame: evaluation as an anticonvulsant. Epilepsia. 1974 Sep;15(3):329-349.
Hansen JM, Kristensen M, Skovsted L. Sulthiame (Ospolot) as inhibitor of diphenylhydantoin metabolism. Epilepsia. 1968 Mar;9(1):17-22.
Houghton GW, Richens A. Phenytoin intoxication induced by sulthiame in epileptic patients. J Neurol Neurosurg Psychiatry. 1974 Mar;37(3):275-281.
Kramer U, Shahar E, Zelnik N, Lerman-Sagie T, Watemberg N, Nevo Y, Ben-Zeev B. Carbamazepine versus sulthiame in treating benign childhood epilepsy with centrotemporal spikes. J Child Neurol. 2002 Dec;17(12):914-916.
Latham AN, Sweeney GD. Binding of anticonvulsant drugs to cytochrome P-450: correlation with evidence of induction of hepatic microsomal enzymes. Can J Physiol Pharmacol. 1976 Dec;54(6):844-849.
Leniger T, Wiemann M, Bingmann D, Widman G, Hufnagel A, Bonnet U. Carbonic anhydrase inhibitor sulthiame reduces intracellular pH and epileptiform activity of hippocampal CA3 neurons. Epilepsia. 2002 May;43(5):469-474.
Madeja M, Wolf C, Speckmann EJ. Reduction of voltage-operated sodium currents by the anticonvulsant drug sulthiame. Brain Res. 2001 May 4;900(1):88-94.
Masuda Y, Shiraishi Y, Karasawa T, Yoshida K, Shimizu M. Differential antagonisms of anticonvulsants to various components of maximal seizures induced by electroshock or pentylenetetrazol in mice. J Pharmacobiodyn. 1980 Oct;3(10):526-531.
May TW, Korn-Merker E, Rambeck B, Boenigk HE. Pharmacokinetics of sulthiame in epileptic patients. Ther Drug Monit. 1994 Jun;16(3):251-257.
McTague A, Cross JH. Treatment of epileptic encephalopathies. CNS Drugs. 2013 Mar;27(3):175-184.
Milburn-McNulty P, Powell G, Sills GJ, Marson AG. Sulthiame add-on therapy for epilepsy. Cochrane Database Syst Rev. 2013 Mar 28;3:CD009472.
Miyajima T, Kumada T, Kimura N, Mikuni T, Fujii T. [Sulthiame treatment for patients with intractable epilepsy]. No To Hattatsu. 2009 Jan;41(1):17-20. Japanese.
Perucca E. Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokinet. 1982 Jan-Feb;7(1):57-84.
Rating D, Wolf C, Bast T. Sulthiame as monotherapy in children with benign childhood epilepsy with centrotemporal spikes: a 6-month randomized, double-blind, placebo-controlled study. Sulthiame Study Group. Epilepsia. 2000 Oct;41(10):1284-1288.
Rockley GJ. Attempted Suicide with Sulthiame. Br Med J. 1965 September 11;2(5462):632.
Shamdeen MG, Jost W, Frohnhöfer M, Gortner L, Meyer S. Effect of sulthiame on EEG pathology, behavior and school performance in children with Rolandic epileptiform discharges. Pediatr Int. 2012 Dec;54(6):798-800.
Stephani U, Carlsson G. The spectrum from BCECTS to LKS: The Rolandic EEG trait-impact on cognition. Epilepsia. 2006;47 Suppl 2:67-70.
Swiderska N, Hawcutt D, Eaton V, Stockton F, Kumar R, Kneen R, Appleton R. Sulthiame in refractory paediatric epilepsies: an experience of an 'old' antiepileptic drug in a tertiary paediatric neurology unit. Seizure. 2011 Dec;20(10):805-808.
Taaffe A, O'Brien C. A case of Stevens-Johnson syndrome associated with the anti-convulsants sulthiame and ethosuximide. Br Dent J. 1975 Mar 4;138(5):172-174.
Temperini C, Innocenti A, Mastrolorenzo A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4866-4872.
Weissbach A, Tirosh I, Scheuerman O, Hoffer V, Garty BZ. Respiratory alkalosis and metabolic acidosis in a child treated with sulthiame. Pediatr Emerg Care. 2010 Oct;26(10):752-753.
Wirrell E, Ho AW, Hamiwka L. Sulthiame therapy for continuous spike and wave in slow-wave sleep. Pediatr Neurol. 2006 Sep;35(3):204-208.

Chapter 5

Anand JS, Chodorowski Z, Wisniewski M. Seizures induced by topiramate overdose. Clin Toxicol (Phila). 2007;45(2):197.
Araki Y, Minakawa EN, Ono M, Matsumoto R, Kinoshita M. Topiramate add-on therapy for adult patients with refractory epilepsy in Japan. Epilepsy & Seizure 2013;6:10-18.
Bialer M, Doose DR, Murthy B, Curtin C, Wang SS, Twyman RE, Schwabe S. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet. 2004;43(12):763-780.
Blum D, Meador K, Biton V, Fakhoury T, Shneker B, Chung S, Mills K, Hammer A, Isojärvi J. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology. 2006 Aug 8;67(3):400-406.
Brandes JL. Practical use of topiramate for migraine prevention. Headache. 2005 Apr;45 Suppl 1:S66-73.
Byung IL. Low dose and slow titration of topiramate as adjunctive therapy in refractory partial epilepsies: a multicenter open clinical trial. Seizure 2002;11:255-260.
Cho YJ, Heo K, Kim WJ, Jang SH, Jung YH, Ye BS, Song DB, Lee BI. Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study. Epilepsia 2009; 50:1910-1919.
Dahlin MG, Beck OM, Amark PE. Plasma levels of antiepileptic drugs in children on the ketogenic diet. Pediatr Neurol. 2006 Jul;35(1):6-10.
Fakhoury T, Murray L, Seger D, McLean M, Abou-Khalil B. Topiramate Overdose: Clinical and Laboratory Features. Epilepsy Behav. 2002 Apr;3(2):185-189.
Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, Karim RM, and the Topiramate YD Study Group. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600mg-daily dosages. Neurology 1996;46:1684-1690.
French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ, Turk WR, Fischer JH, Bourgeois B, Wilner A, R.E. Faught REJ, Sachdeo RC, Beydoun A, Glauser TA. Efficacy and tolerability of the new antiepileptic drugs II. Epilepsia 2004;45:410-423.
Guberman A, Neto W, Gassmann-Mayer C, Low-dose topiramate in adults with treatment-resistant partial- onset seizures. Acta Neurol Scand 2002:106:183-189.
Guerrini R, Parmeggiani L. Topiramate and its clinical applications in epilepsy. Expert Opin Pharmacother 2006;7:811-823.
Hunt S, Russell A, Smithson WH, Parsons L, Robertson I, Waddell R, Irwin B, Morrison PJ, Morrow J, Craig J, UK Epilepsy and Pregnancy Register. Topiramate in Pregnancy: Preliminary Experience from the UK Epilepsy and Pregnancy Register. Neurology 2008;71(4):272–276.
Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther. 2013 Jan;95(1):53-66.
Korean Topiramate Study Group. Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Korean Topiramate Study Group. Epilepsia 1999;40:1767-1774.
Krakow K, Lengler U, Rettig K, Schreiner A, Schauble B; TOP-GER-3 investigators. Topiramate in add-on therapy: results from an open-label, observational study. Seizure 2007;16:593-600.
Langman LJ, Kaliciak HA, Boone SA. Fatal acute topiramate toxicity. J Anal Toxicol. 2003 Jul-Aug;27(5):323-324.
LaRoche SM. A new look at the second-generation antiepileptic drugs: A decade of experience. Neurologist 2007;13:133-139.
Lofton AL, Klein-Schwartz W. Evaluation of toxicity of topiramate exposures reported to poison centers. Hum Exp Toxicol. 2005 Nov;24(11):591-595.
Lynch MJ, Pizon AF, Siam MG, Krasowski MD. Clinical effects and toxicokinetic evaluation following massive topiramate ingestion. J Med Toxicol. 2010 Jun;6(2):135-138.
Lyseng-Williamson KA, Yang LP. Topiramate: a review of its use in the treatment of epilepsy. Drugs. 2007;67(15):2231-2256.
Matsuda K, Yagi K. Topiramate placebo-controlled trial in partial epilepsy- Phase Ш trial. Shinyaku to Rinsho 2007;56:1385-1403.
Minakawa EN, Matsumoto R, Kinoshita M. Topiramate induced agranulocytosis. BMJ Case Reports 2009; doi:10.1136.
Ohman I, Vitols S, Luef G, Söderfeldt B, Tomson T. Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia. 2002 Oct;43(10):1157-1160.
Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet. 2006;45(4):351-363.
Pugh MJ, Copeland LA, Zeber JE, Wang CP, Amuan ME, Mortensen EM, Tabares JV, Van Cott AC, Cooper TL, Cramer JA. Antiepileptic drug monotherapy exposure and suicide-related behavior in older veterans. J Am Geriatr Soc. 2012 Nov;60(11):2042-2047.
Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G, and the Topiramate YL Study Group. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 1999;52:1882-1887.
Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, Mather GG, Roskos LK, Shen DD, Thummel KE, Trager WF, Curtin CR, Doose DR, Gisclon LG, Bialer M. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia. 2002 Jul;43(7):691-696.
Silberstein SD. Topiramate in migraine prevention. Headache. 2005 Apr;45 Suppl 1:S57-65.
St. Giannakodimos ST, Georgiadis G, Tsounis ST, Triantafillou N, Kimiskidis V, Giatas K, Karlovasitou A, Mitsikostas DD, Thodi E, Polychronopoulos P, Ramopoulos N, Michailidis N, Michalis N, Garganis K, Gatzonis ST, Balogiannis ST, Kazis AR, Milonas J, Van Oene JC. Add-on topiramate in the treatment of refractory partial-onset epilepsy: Clinical experience of outpatient epilepsy clinics from 11 general hospitals. Seizure 2005;14:396-402.
Yanovski SZ, Yanovski JA. Long-term Drug Treatment for Obesity: A Systematic and Clinical Review. JAMA. 2013 Nov 14, Epub ahead of press.
Yen DJ, Yu HY, Guo YC, Chen C, Yiu CH, Su MS. A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia 2000;41:1162-1166.
Wang PW, Ketter TA, Becker OV, Nowakowska C. New anticonvulsant medication uses in bipolar disorder. CNS Spectr. 2003 Dec;8(12):930-932, 941-947.
Wiśniewski M, Łukasik-Głebocka M, Anand JS. Acute topiramate overdose--clinical manifestations. Clin Toxicol (Phila). 2009 Apr;47(4):317-320.

Chapter 6

Bazil CW. Anticonvulsant drug or neuromodulator? The growing case for anticonvulsant uses beyond epilepsy. Curr Neurol Neurosci Rep. 2004;4:305-307.
Bermejo PE, Zabala JA, Saez R. Restless legs syndrome induced by zonisamide. Mov Disord. 2007;22:1517-1518.
Bermejo PE. Zonisamide in patients with essential tremor and Parkinson's disease. Mov Disord. 2007 Oct 31;22(14):2137-2138.
Bermejo PE, Ruiz-Huete C, Dorado R, Anciones B. [Zonisamide in refractory essential tremor]. Rev Neurol. 2008 Feb 1-15;46(3):139-142. Spanish.
Bermejo PE, Ruiz-Huete C, Anciones B. Zonisamide in managing impulse control disorders in Parkinson's disease. J Neurol. 2010 Oct;257(10):1682-1685.
Bermejo PE, Anciones B. A review of the use of zonisamide in Parkinson's disease. Ther Adv Neurol Disord. 2009 Sep;2(5):313-317.
Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-240.
Bookheimer S, Schrader LM, Rausch R, Sankar R, Engel J Jr. Reduced anesthetization during the intracarotid amobarbital (Wada) test in patients taking carbonic anhydrase-inhibiting medications. Epilepsia. 2005 Feb;46(2):236-243.
Brodie MJ, Duncan R, Vespignani H, Solyom A, Bitenskyy V, Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia. 2005 Jan;46(1):31-41.
Carlson H, Ronne-Engström E, Ungerstedt U, Hillered L. Seizure related elevations of extracellular amino acids in human focal epilepsy. Neurosci Lett. 1992 Jun 8;140(1):30-32.
Carod-Artal FJ, Ziomkowski S, Mourão Mesquita H, Martínez-Martin P. Anxiety and depression: main determinants of health-related quality of life in Brazilian patients with Parkinson's disease. Parkinsonism Relat Disord. 2008;14(2):102-108.
Cavanna AE, Seri S. Psychiatric adverse effects of zonisamide in patients with epilepsy and mental disorder comorbidities. Epilepsy Behav. 2013 Nov;29(2):281-284.
Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD001416.
Chen JT, Garcia PA, Alldredge BK. Zonisamide-induced restless legs syndrome. Neurology. 2003 Jan 14;60(1):147.
Cloyd JC, Remmel RP. Antiepileptic drug pharmacokinetics and interactions: impact on treatment of epilepsy. Pharmacotherapy. 2000 Aug;20(8 Pt 2):139S-151S.
Conry JA. Pharmacologic treatment of the catastrophic epilepsies. Epilepsia. 2004;45 Suppl 5:12-16.
Dauphinais D, Knable M, Rosenthal J, Polanski M, Rosenthal N. Zonisamide for bipolar disorder, mania or mixed states: a randomized, double blind, placebo-controlled adjunctive trial. Psychopharmacol Bull. 2011;44(1):5-17.
Eisai Inc 2004. Zonegran [package insert]: Teaneck, NJ, USA: Eisai Inc.
Faught E, Ayala R, Montouris GG, Leppik IE; Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology. 2001 Nov 27;57(10):1774-1779.
Fukushima K, Seino M. A long-term follow-up of zonisamide monotherapy. Epilepsia. 2006 Nov;47(11):1860-1864.
Ghanizadeh A, Nikseresht MS, Sahraian A. The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. Schizophr Res. 2013 Jun;147(1):110-115.
Glauser TA, Pellock JM. Zonisamide in pediatric epilepsy: review of the Japanese experience. J Child Neurol. 2002 Feb;17(2):87-96.
Gluck MR, Santana LA, Granson H, Yahr MD. Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity. J Neural Transm. 2004 Jun;111(6):713-724.
Goldfarb DS. A woman with recurrent calcium phosphate kidney stones. Clin J Am Soc Nephrol. 2012 Jul;7(7):1172-1178.
Gómez-Esteban JC, Zarranz JJ, Tijero B, Velasco F, Barcena J, Rouco I, Lezcano E, Lachen MC, Jauregui A, Ugarte A. Restless legs syndrome in Parkinson's disease. Mov Disord. 2007 Oct 15;22(13):1912-1916.
Griffith SG, Dai Y. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. Clin Ther. 2004 Dec;26(12):2056-2065.
Hashimoto Y, Odani A, Tanigawara Y, Yasuhara M, Okuno T, Hori R. Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. Biol Pharm Bull. 1994 Feb;17(2):323-326.
Hayakawa T, Higuchi Y, Nigami H, Hattori H. Zonisamide reduces hypoxic-ischemic brain damage in neonatal rats irrespective of its anticonvulsive effect. Eur J Pharmacol. 1994 May 12;257(1-2):131-136.
Henry TR, Leppik IE, Gumnit RJ, Jacobs M. Progressive myoclonus epilepsy treated with zonisamide. Neurology. 1988 Jun;38(6):928-931.
Hofer KE, Trachsel C, Rauber-Lüthy C, Kupferschmidt H, Kullak-Ublick GA, Ceschi A. Moderate toxic effects following acute zonisamide overdose. Epilepsy Behav. 2011 May;21(1):91-93.
Huang CW, Ueno S, Okada M, Kaneko S. Zonisamide at clinically relevant concentrations inhibits field EPSP but not presynaptic fiber volley in rat frontal cortex. Epilepsy Res. 2005 Oct-Nov;67(1-2):51-60.
Jankovic J. An update on the treatment of Parkinson's disease. Mt Sinai J Med. 2006 Jul;73(4):682-689.
Kajimoto Y, Nakanishi I, Kondo Wakayama T. One year follow-up study of the zonisamide (ZNS) efficacy on parkinsonism. Mov Disord. 2008;23(Suppl 1):214 [Abstract].
Kashihara K. Weight loss in Parkinson's disease. J Neurol. 2006 Dec;253 Suppl 7:VII38-41.
Kawata Y, Okada M, Murakami T, Mizuno K, Wada K, Kondo T, Kaneko S. Effects of zonisamide on K+ and Ca2+ evoked release of monoamine as well as K+ evoked intracellular Ca2+ mobilization in rat hippocampus. Epilepsy Res. 1999 Jul;35(3):173-182.
Kinrys G, Vasconcelos e Sa D, Nery F. Adjunctive zonisamide for treatment refractory anxiety. Int J Clin Pract. 2007 Jun;61(6):1050-1053.
Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure. 1996 Jun;5(2):115-119.
Kochak GM, Page JG, Buchanan RA, Peters R, Padgett CS. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharmacol. 1998 Feb;38(2):166-171.
Komatsu M, Okamura Y, Hiramatsu M. Free radical scavenging activity of zonisamide and its inhibitory effect on lipid peroxide formation in iron-induced epileptogenic foci of rats. Neurosciences. 1995;21:23-29.
Kondo T, Kaneko S, Amano Y, Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia. 1996 Dec;37(12):1242-1244.
Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology. 2000 Apr 25;54(8):1589-1595.
Kothare SV, Valencia I, Khurana DS, Hardison H, Melvin JJ, Legido A. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord. 2004 Dec;6(4):267-270.
Kubo M, Nishikawa N, Yabe H, Nagai M, Moritoyo H, Moritoyo T. Zonisamide increased metabolism of dopamine neurons in MPTP-treated C57BL/6 and common marmosets. Mov Disord. 2008;23(Suppl 1):311 [Abstract].
Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res. 1998 Jan;29(2):109-114.
Leppik IE. Zonisamide. Epilepsia. 1999;40(Suppl 5):S23-29.
Leppik IE. Classifi cation of the myoclonic epilepsies. Epilepsia. 2003;44(Suppl 11):2-6.
Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004;13(Suppl 1):S5-9.
Levy RH, Ragueneau-Majlessi I, Brodie MJ, Smith DF, Shah J, Pan WJ. Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. Ther Drug Monit. 2005 Apr;27(2):193-198.
Lotze TE, Wilfong AA. Zonisamide treatment for symptomatic infantile spasms. Neurology. 2004;62:296–298.
Masuda Y, Utsui Y, Shiraishi Y, Karasawa T, Yoshida K, Shimizu M. Relationships between plasma concentrations of diphenylhydantoin, phenobarbital, carbamazepine, and 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810), a new anticonvulsant agent, and their anticonvulsant or neurotoxic effects in experimental animals. Epilepsia. 1979 Dec;20(6):623-633.
McElroy SL, Winstanley E, Mori N, Martens B, McCoy J, Moeller D, Guerdjikova AI, Keck PE Jr. A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain. J Clin Psychopharmacol. 2012 Apr;32(2):165-172.
Michael CT, Starr JL. Psychosis following initiation of zonisamide. Am J Psychiatry. 2007 Apr;164(4):682.
Miura H. Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. Seizure. 2004;13(Suppl 1):S17-23.
Mirza NS, Alfirevic A, Jorgensen A, Marson AG, Pirmohamed M. Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors. Pharmacogenet Genomics. 2011 May;21(5):297-302.
Mohammadianinejad SE, Abbasi V, Sajedi SA, Majdinasab N, Abdollahi F, Hajmanouchehri R, Faraji A. Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial. Clin Neuropharmacol. 2011 Jul-Aug;34(4):174-177.
Mori A, Noda Y, Packer L. The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res. 1998;30:153-158.
Mori A, Yokoi I, Noda Y, Willmore LJ. Natural antioxidants may prevent posttraumatic epilepsy: a proposal based on experimental animal studies. Acta Med Okayama. 2004 Jun;58(3):111-118.
Murata M, Horiuchi E, Kanazawa I. Zonisamide has beneficial effects on Parkinson’s disease patients. Neurosci Res. 2001;41:397-399.
Murata M, Hasegawa K, Kanazawa I. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology. 2007;68:45-50.
Nakanishi I, Kohmoto J, Miwa H, Kondo T. [Effect of zonisamide on resting tremor resistant to antiparkinsonian medication]. No To Shinkei. 2003 Aug;55(8):685-689. Japanese.
Nakasa H, Komiya M, Ohmori S, Rikihisa T, Kiuchi M, Kitada M. Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. Mol Pharmacol. 1993;44:216-221.
Noda Y, Mori A, Packer L. Zonisamide inhibits nitric oxide synthase activity induced by N-methyl-D-aspartate and buthionine sulfoximine in the rat hippocampus. Res Commun Mol Pathol Pharmacol. 1999;105:23-33.
Noguchi T, Fukatsu N, Kato H, Oshima T, Kanemoto K. Impact of antiepileptic drugs on genesis of psychosis. Epilepsy Behav. 2012 Apr;23(4):462-465.
Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, Fukushima Y. Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995;22:193-205.
Okada M, Kawata Y, Mizuno K, Wada K, Kondo T, Kaneko S. Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br J Pharmacol. 1998;124:1277-1285.
Okada M, Hirano T, Kawata Y, Murakami T, Wada K, Mizuno K, Kondo T, Kaneko S. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res. 1999;34:187-197.
Ondo WG. Zonisamide for essential tremor. Clin Neuropharmacol. 2007;30:345-349.
Owen AJ, Ijaz S, Miyashita H, Wishart T, Howlett W, Shuaib A. Zonisamide as a neuroprotective agent in an adult gerbil model of global forebrain ischemia: a histological, in vivo microdialysis and behavioral study. Brain Res. 1997;770:115-122.
Peters DH, Sorkin EM. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs. 1993 May;45(5):760-787.
Ragueneau-Majlessi I, Levy RH, Brodie M, Smith D, Shah J, Grundy JS. Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. Clin Pharmacokinet. 2005;44:517-523.
Rock DM, Macdonald RL, Taylor CP. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res. 1989;3:138-143.
Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med. 2004;10:685-692.
Sackellares JC, Ramsay RE, Wilder BJ, Browne TR 3rd, Shellenberger MK. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia. 2004;45:610-617.
Santos CC, Brotherton T. Use of zonisamide in pediatric patients. Pediatr Neurol. 2005;33:12-14.
Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res. 1987;413:185-188.
Schmidt D, Jacob R, Loiseau P, Deisenhammer E, Klinger D, Despland A, Egli M, Bauer G, Stenzel E, Blankenhorn V. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. 1993;15:67-73.
Schwartzkroin PA. Arresting epileptogenesis: the current challenge. In Rho JM, Sankar R, Cavazos JE (eds). Epilepsy: scientific foundations of clinical practice. New York: Marcel Dekker Inc. p 483-96. 2004.
Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat. 2013;23(6):725-735.
Seino M. Review of zonisamide development in Japan. Seizure. 2004;13(Suppl 1):S2-4.
Seki T, Kumagai N, Maezawa M. Effects of zonisamide monotherapy in children with epilepsy. Seizure. 2004;13(Suppl 1):S26-32.
Stiff DD, Robicheau JT, Zemaitis MA. Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative. Xenobiotica. 1992;22:1-11.
Sudha K, Rao AV, Rao A. Oxidative stress and antioxidants in epilepsy. Clin Chim Acta. 2001;303:19-24.
Suzuki S, Kawakami K, Nishimura S, Watanabe Y, Yagi K, Seino M, Miyamoto K. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res. 1992;12:21-27.
Suzuki Y, Nagai T, Ono J, Imai K, Otani K, Tagawa T, Abe J, Shiomi M, Okada S. Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia. 1997 Sep;38(9):1035-1038.
Tomson T. Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding. Ther Drug Monit. 2005 Dec;27(6):718-721.
Ueda Y, Doi T, Tokumaru J, Willmore LJ. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res. 2003 Aug 19;116(1-2):1-6.
Vossler DG, Conry JA, Murphy JV; ZNS-502/505 PME Study Group. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. Epileptic Disord. 2008 Mar;10(1):31-34.
Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res. 1998;29:147-154.
Welty TE, Kuzniecky RI, Faught E. Newer antiepilepsy drug outcomes in juvenile myoclonic epilepsy patients. Epilepsia. 2004;45(Suppl 7):145-146 [Abstract].
White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia. 1999;40(Suppl 5):S2-10.
Wichmann T, DeLong MR. Basal ganglia discharge abnormalities in Parkinson’s disease. J Neural Transm. 2006;70:21-25.
Wilfong AA. Zonisamide monotherapy for epilepsy in children and young adults. Pediatr Neurol 2005;32:77-80.
Wilfong A, Schultz R. Zonisamide for absence seizures. Epilepsy Res. 2005;64:31-34.
Willmore LJ. Antiepileptic drugs and neuroprotection: current status and future roles. Epilepsy Behav. 2005;7(Suppl. 3):25-28.
Wilson MS, Findling RL. Zonisamide for bipolar depression. Expert Opin Pharmacother. 2007 Jan;8(1):111-113.
Yamauchi T, Aikawa H. Efficacy of zonisamide: our experience. Seizure. 2004 Dec;13 Suppl 1:S41-8; discussion S49.
Zesiewicz TA, Ward CL, Hauser RA, Sanchez-Ramos J, Staffetti JF, Sullivan KL. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Mov Disord. 2007;22:279-282.
Zhu W, Rogawski MA. Zonisamide depresses excitatory synaptic transmission by a presynaptic action. Epilepsia. 1999;40(Suppl 7):245 [Abstract].

You have not viewed any product yet.